Wound cleansing & irrigation
Development for wound cleansing, irrigation, debridement and prevention. Ukraine pilot studies are planned for early 2027, with registration targeted for Q4 2026–Q1 2027 and national launch in H2 2027.
In development
Science in service of healing
SoftOx
WoundCare
Next Generation Antimicrobial
Advancing a new approach to biofilm in infected and chronic wounds. Helping create the conditions for healing.
The unmet need
Healing starts with
addressing biofilm.
Biofilm protects bacteria and can keep wounds in a persistent state of inflammation. For patients living with chronic wounds, this remains a significant barrier to healing.
A persistent barrier
Bacteria within biofilm are difficult to address with conventional antimicrobial approaches.3
An unmet need
Unhealed wounds account for about two-thirds of wound care costs and today's antiseptics and antibiotics do not adequately address biofilms.
TECHNOLOGY - Our solution
Inspired by nature.
Developed through science.
SoftOx WoundCare Biofilm Eradicator (SBE) combines stabilised hypochlorous acid with acetic acid in an optimised antimicrobial formulation. The SBE delivers clinical efficacy against infections and biofilm with superior outcome.
The antimicrobial
Hypochlorous acid
A molecule also produced by the body's immune cells.
The stabiliser
Acetic acid
Combined with HOCl in our optimised formulation.
A targeted approach to biofilm
Simplified mechanism · laboratory & early clinical findingsEarly first‑in‑human results in chronic leg ulcers indicate accelerated wound healing and activity against WHO‑priority resistant bacteria and biofilm.4
One formulation / Two development paths
A complementary path forward.
Therapeutic antimicrobial
Pharmaceutical development for infected, hard-to-heal wounds, with venous leg ulcers as the lead indication. Phase 1a/1b is complete with early positive signals and positive FDA pre-IND feedback; US Phase 3 is planned for late 2027.
Clinical developmentFaster healing leads to large savings
Fewer weeks of dressing changes and nursing visits, fewer wounds becoming chronic, fewer amputations and admissions, and less systemic antibiotic use.
Source: SoftOx MedValue decision model (Markov VLU/DFU sheets). USD per patient, discounted 3%/yr; SoftOx price not included. Modelled, not clinical results.Clinical Evidence
Encouraging signals.
A rigorous path forward.
Completed Phase 1a/1b studies in chronic leg ulcers provide early wound-healing signals, a dose-response pattern and an encouraging safety profile. Ukraine pilot studies are intended to support progression to a US Phase 3 trial.
0 SAE
No serious adverse events reported
Across the Phase 1a and Phase 1b studies (n=28), as reported in the company material.1
98%Bacterial-load reduction
After a 20-minute soak, compared with 49% for saline.1 An early microbiological endpoint—not a wound-closure result.
Median wound-area reduction
Five days of treatment · follow-up at day 7
Placebo−1.9%
SBE Once daily12.5%
SBE Twice daily36.1%
Group medians; small exploratory comparison (n=4 per arm). 500 ppm HOCl + 2% acetic acid. The negative placebo value indicates an increase in wound area. Source: SBE-01.4
Bacterial-load reduction
After a 20-minute soak (%)
Saline49%
SBE98%
Compared with saline in a biofilm wound model. An early microbiological endpoint, not a wound-closure result.1
SBE is investigational. These early findings do not establish clinical efficacy or regulatory approval.
- Fazli MM, Kirketerp-Møller K, Sonne DP, et al. Advances in Wound Care (New Rochelle). 2024;13(11):529–541. Early clinical findings.
- Malone M, Bjarnsholt T, McBain AJ, et al. Journal of Wound Care. 2017;26(1):20–25. Biofilm prevalence in chronic wounds.
- Schultz G, Bjarnsholt T, James GA, et al. Wound Repair and Regeneration. 2017;25(5):744–757. Consensus guidance on wound biofilm.
- SoftOx study SBE-01, Table 14.3.8.1 (12 October 2022). Wound area, full analysis set. Internal study source cited in the supplied company material.
- Coelho MMF, Avelino BMA, de Oliveira BA, et al. Wounds. 2025;37(8):283–291. Biofilm in chronic wounds.
Company
A clear focus.
An international perspective.
SoftOx WoundCare is an independent medical company focused on developing a new class of antimicrobial for infected and chronic wounds. Built on 15 years of product development, we bring together specialist expertise as needed in a lean organisation, with patent protection until 2043.
Purpose
Advancing healing, transforming tomorrow.
Locations
Where we operate
Sweden
SoftOx WoundCare AB
Holding company · Malmö
Switzerland
SoftOx WoundCare Commercial
& Management AG
Commercialisation & management
Planned 2027Norway
SoftOx Wound & Skincare AS
Global support office
People
Management and Board 2027
Management team
Geir Almås
CEO · Chief Business Development Officer
Outgoing CEO · until end of 2026Gabriel Bennet
CEO
Planned · from 2027Ingrid Juven
CFO · Finance, IR, Communication & Operations
Tetyana Golofiyevska
Chief Commercial Officer
Dr. Edwin den Braber
Chief Medical Officer
Sverre Bernhardsen
Head of IT
Frida Terne
Chemistry Manufacturing Control Officer
Josefin Jönsson
QA Officer
Board of directors
Geir Almås
Chairman
Outgoing · until end of 2026Dr. Ralf Schmidt
Chairman
Planned · from 2027Independent director
To be announced
Independent director
To be announced
Gabriel Bennet
Board member
Planned CEO · from 2027The 2027 CEO and chairman appointments are planned leadership transitions.
Timeline
Research-led with
strong execution.
From a patented idea to early clinical research, our development is guided by a clear goal: addressing the needs of hard-to-heal wounds.
Founded in Oslo
Founded in Oslo on patented antimicrobial technology.
University of Copenhagen
Start of collaboration with University of Copenhagen (Prof. Thomas Bjarnsholt).
Stock exchange listing
Listed on Merkur Oslo Stock Exchange (SOFTOX-ME).
US Navy contract
Sponsor contract established with the US Navy (wound care).
SWIS-02 wound study
SWIS-02 wound study: faster early healing than saline.
SIS Phase 1 completed
SIS Phase 1 completed – safe to inhale.
EU COUNTERACT grant
EU COUNTERACT defence grant (CBRN) signed.
SBE Report Phase 1
Safe in human with 98% bacterial reduction, 36% wound closure.
Restructuring
Restructuring; R&D to University of Copenhagen; wound care spin-out announced.
Wound & Skin Care demerged
SoftOx Wound & Skin Care demerged to shareholders (1:1).
The next chapter / Planned milestonesSoftOx WoundCare:
SoftOx WoundCare:
moving forward.
Denmark pre-clinical study
Successfully kills pathogens within the biofilm.
US Navy sponsor contract
Sponsor contract established with the US Navy (wound care).
SWIS-02 wound study
Faster early healing than saline.
SBE Report Phase 1
Safe in human with 98% bacterial reduction, 36% wound closure.
Study publication
Publication of stabilised hypochlorous acid in chronic leg ulcers.
Demerger
SoftOx WoundCare demerged, becoming independent and developing SBE.
First MD registration
First medical-device registration ongoing in Ukraine; industrial partnership with local partner.
Equity partner
Equity partner with additional financing. New management. Ukraine MD proof of concept.
US Phase 3
Commencing US Phase 3 Adaptive Design Clinical Trials. Considering listing in the US.
Commercialisation planning
Detailed planning of commercialisation SBE US. Launch of MD RoW.
Market launch
Market launch of SBE US and Europe.
New product areas
Trials and launch of new product areas.
End of existing patents
End of existing patents.
Planned milestones are estimates, not commitments, and depend on financing, clinical results and regulatory decisions.
Contact - Get in touch
Let's move wound
care forward.
For commercial partnerships and company enquiries.
contact@softox-woundcare.com
SoftOx WoundCare AB
Slottsgatan 20
211 33 Malmö, Sweden